

U.S. Serial No. 09/142,043

In the Claims:

Please amend the claims to read as follows:

Sub #1
37. (Three times amended) A polypeptide comprising a 6 to 23 amino acid portion of SEQ ID NO: 1, wherein the polypeptide has at least one amino acid sequence selected from the group consisting of :

G1
(a) amino acids 6-11 OF SEQ ID NO: 1, and

(b) amino acids 11-20 of SEQ ID NO: 1 , wherein the isolated polypeptide does not comprise a mature short consensus repeat-3.

Sub #2
G2
38. (Amended) The polypeptide according to claim 37, further comprising a cysteine residue at the carboxyl terminus and the amino terminus of the polypeptide, thereby providing a capability to form a cyclic polypeptide via formation of a disulfide bond.

Sub #3
G3
39. (Twice amended) The polypeptide according to claim 37, further comprising a chemically reactive amino acid residue located at least one position selected from the group consisting of the carboxyl terminus and the amino terminus of the polypeptide.

U.S. Serial No. 09/142,043

Sub #4
40. (Amended) The polypeptide according to claim 39, wherein the chemically reactive amino acid residue is derivatized or derivatizable.

G4
41. (Amended) The polypeptide according to claim 40, wherein the terminal amino acid residue is cysteine derivatized with S- (2-pyridyl) dithio.

42. (Amended) The polypeptide according to claim 37, wherein the polypeptide is altered to remove chemically reactive amino acids.

Sub #5
G4
43. (Three times amended) A multimeric polypeptide comprising at least two polypeptide constituents that comprise a 6 to 23 amino acid portion of SEQ ID NO: 1, wherein the polypeptide constituents have at least one amino acid sequence selected from the group consisting of:

(a) amino acids 6-11 OF SEQ ID NO: 1, and

(b) amino acids 11-20 of SEQ ID NO: 1, wherein the polypeptide constituents do not comprise a mature short consensus repeat-3 and the polypeptide constituents are linked to a core structure.

Sub #6
G5
44. (Amended) The multimeric polypeptide according to claim 43, wherein the core structure comprises a derivative of lysine.

U.S. Serial No. 09/142,043

Sub H9

48. (Three times amended) A chimeric polypeptide comprising a host protein and an insert polypeptide comprising a 6 to 23 amino acid portion of SEQ ID NO: 1, wherein the polypeptide has at least one amino acid sequence selected from the group consisting of:

- G6*
- (a) amino acids 6-11 of SEQ ID NO: 1, and
 - (b) amino acids 11-20 of SEQ ID NO: 1, wherein the insert polypeptide is inserted in a region of the host protein, and the insert polypeptide does not comprise a mature short consensus repeat-3.

Sub H11

52. (Three times amended) A process for preparing a polypeptide comprising a 6 to 23 amino acid portion of SEQ ID NO: 1, wherein the polypeptide has at least one amino acid sequence selected from the group consisting of:

- G7*
- (a) amino acids 6-11 of SEQ ID NO: 1, and
 - (b) amino acids 11-20 of SEQ ID NO: 1, and the polypeptide does not comprise a mature short consensus repeat-3, comprising the step of: condensing peptide units.

U.S. Serial No. 09/142,043

53. (Three times amended) A process for preparing a polypeptide comprising a 6 to 23 amino acid portion of SEQ ID NO: 1, wherein the polypeptide has at least one amino acid sequence selected from the group consisting of:

(a) amino acids 6-11 of SEQ ID NO: 1, and

(b) amino acids 11-20 of SEQ ID NO: 1, and the polypeptide does not comprise a mature short consensus repeat-3, comprising the step of: expressing DNA encoding the polypeptide in a recombinant host cell, and recovering the polypeptide.

54. (Three times amended) An isolated polynucleotide encoding a polypeptide comprising a 6 to 23 amino acid portion of SEQ ID NO: 1, wherein the polypeptide has at least one amino acid sequence selected from the group consisting of:

(a) amino acids 6-11 of SEQ ID NO: 1, and

(b) amino acids 11-20 of SEQ ID NO: 1, and the polypeptide does not comprise a mature short consensus repeat-3.

U.S. Serial No. 09/142,043

57. (Three times amended) A pharmaceutical composition comprising

(1) a therapeutically effective amount of a polypeptide comprising a 6 to 23 amino acid portion of SEQ ID NO: 1, wherein the polypeptide has at least one amino acid sequence selected from the group consisting of:

(a) amino acids 6-11 of SEQ ID NO: 1, and

(b) amino acids 11-20 of SEQ ID NO: 1, and the polypeptide does not comprise a mature short consensus repeat-3, and

(2) a pharmaceutically acceptable carrier or excipient.